Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Epoetin→

Epoetin Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
113427-24-0
Molecular formula
C809H1301N229O240S5
Molecular weight
~30400 g/mol
Drug class
Erythropoiesis-stimulating agent (ESA)recombinant human erythropoietin biologic
Mechanism of action
Binds erythropoietin receptors on erythroid progenitor cells in bone marrow, stimulating survival, proliferation and differentiation of erythroid precursors and increasing red blood cell production.
Indications / reported uses
  • Treatment of anaemia associated with chronic kidney disease in selected patients
  • Treatment of zidovudine-associated anaemia in selected patients with HIV infection
  • Treatment of anaemia in selected patients with non-myeloid malignancies receiving myelosuppressive chemotherapy
  • Reduction of allogeneic red blood cell transfusion requirements in selected patients undergoing elective, non-cardiac, non-vascular surgery; indications are specific to the epoetin product label

Sources: US DailyMed — EPOGEN (epoetin alfa) · US DailyMed — PROCRIT (epoetin alfa) · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Epoetin Environmental Risk Assessment (ERA) (the Epoetin ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.